Sera Prognostics (SERA) 10-Q30 Aug 212021 Q2 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2021	Aug. 25, 2021
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Entity File Number	001-40606
Entity Registrant Name	SERA PROGNOSTICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1911522
Entity Address, Address Line One	2749 East Parleys Way
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84109
City Area Code	801
Local Phone Number	990-0520
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Trading Symbol	SERA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,293,831
Entity Central Index Key	0001534969
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 90,851	$ 13,533
Accounts receivable	14	2
Prepaid expenses and other current assets	503	198
Total current assets	91,368	13,733
Property and equipment, net	871	965
Other assets	2,828	98
Total assets	95,067	14,796
Current liabilities:
Accounts payable	1,026	441
Accrued and other current liabilities	1,997	1,577
Accrued interest on convertible note	0	996
Deferred rent, current portion	138	130
Capital lease obligation, current portion	71	69
Convertible promissory note, current portion	0	4,353
Loans payable, current portion	0	3,676
Total current liabilities	3,232	11,242
Deferred rent	69	139
Loans payable, net of current portion	0	348
Preferred stock warrant liability	485	474
Capital lease obligation, net of current portion	91	127
Total liabilities	3,877	12,330
Commitments and contingencies
Stockholders' deficit:
Additional paid-in capital	8,327	5,889
Accumulated deficit	(144,125)	(131,459)
Total stockholders' deficit	(135,798)	(125,570)
Total liabilities, convertible preferred stock, and stockholders' deficit	95,067	14,796
Class A common stock
Stockholders' deficit:
Common stock value	0	0
Class B common stock
Stockholders' deficit:
Common stock value	0	0
Junior convertible preferred stock
Convertible preferred stock:
Convertible preferred stock	77,844	77,844
Senior convertible preferred stock
Convertible preferred stock:
Convertible preferred stock	$ 149,144	$ 50,192

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Class A common stock
Common stock, Par Value	$ 0.0001	$ 0.0001
Common stock, Shares Authorized	80,000,000	55,000,000
Common stock, Shares Issued	2,004,955	1,700,625
Common stock, Shares Outstanding	2,004,955	1,700,625
Class B common stock
Common stock, Par Value	$ 0.0001	$ 0.0001
Common stock, Shares Authorized	3,000,000	0
Common stock, Shares Issued	0	0
Common stock, Shares Outstanding	0	0
Junior convertible preferred stock
Convertible preferred stock, Par Value	$ 0.0001	$ 0.0001
Convertible preferred stock, Shares Authorized	22,047,294	20,537,294
Convertible preferred stock, Shares Issued	9,819,480	9,819,480
Convertible preferred stock, Shares Outstanding	9,819,480	9,819,480
Convertible preferred stock, Liquidation preference	$ 78,916	$ 78,916
Senior convertible preferred stock
Convertible preferred stock, Par Value	$ 0.0001	$ 0.0001
Convertible preferred stock, Shares Authorized	29,504,387	12,320,844
Convertible preferred stock, Shares Issued	13,791,579	5,737,440
Convertible preferred stock, Shares Outstanding	13,791,579	5,737,440
Convertible preferred stock, Liquidation preference	$ 202,835	$ 102,535

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Condensed Statements of Operations and Comprehensive Loss
Revenue	$ 20	$ 6	$ 33	$ 14
Operating expenses:
Cost of revenue	8	2	13	6
Research and development	2,824	1,752	5,221	3,801
Selling and marketing	1,740	712	3,090	1,580
General and administrative	2,829	1,821	5,116	3,200
Total operating expenses	7,401	4,287	13,440	8,587
Loss from operations	(7,381)	(4,281)	(13,407)	(8,573)
Interest expense	2	(420)	(305)	(857)
Other income (expense), net	1,072	(4)	1,046	29
Net loss and comprehensive loss	$ (6,307)	$ (4,705)	$ (12,666)	$ (9,401)
Net loss per share, basic and diluted	$ (3.17)	$ (3.08)	$ (6.70)	$ (6.16)
Weighted-average shares of common stock outstanding, basic and diluted	1,988,886	1,525,648	1,890,908	1,525,491

Condensed Statements of Convert

Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Junior convertible preferred stock	Senior convertible preferred stock	Total
Balance at the beginning at Dec. 31, 2019				$ 77,844	$ 39,506
Balance at the beginning (in shares) at Dec. 31, 2019				9,819,480	4,546,024
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of senior convertible preferred stock, net of issuance costs					$ 10,704
Issuance of senior convertible preferred stock, net of issuance costs (in shares)					1,191,416
Balance at the ending at Mar. 31, 2020				$ 77,844	$ 50,210
Balance at the ending (in shares) at Mar. 31, 2020				9,819,480	5,737,440
Balance at the beginning at Dec. 31, 2019		$ 4,987	$ (111,611)			$ (106,624)
Balance at the beginning (in shares) at Dec. 31, 2019	1,525,119
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options		1				1
Issuance of common stock upon exercise of stock options (in shares)	529
Stock-based compensation expense		135				135
Net loss			(4,696)			(4,696)
Balance at the ending at Mar. 31, 2020		5,123	(116,307)			(111,184)
Balance at the ending (in shares) at Mar. 31, 2020	1,525,648
Balance at the beginning at Dec. 31, 2019				$ 77,844	$ 39,506
Balance at the beginning (in shares) at Dec. 31, 2019				9,819,480	4,546,024
Balance at the ending at Jun. 30, 2020				$ 77,844	$ 50,192
Balance at the ending (in shares) at Jun. 30, 2020				9,819,480	5,737,440
Balance at the beginning at Dec. 31, 2019		4,987	(111,611)			(106,624)
Balance at the beginning (in shares) at Dec. 31, 2019	1,525,119
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss						(9,401)
Balance at the ending at Jun. 30, 2020		5,324	(121,012)			(115,688)
Balance at the ending (in shares) at Jun. 30, 2020	1,525,648
Balance at the beginning at Mar. 31, 2020				$ 77,844	$ 50,210
Balance at the beginning (in shares) at Mar. 31, 2020				9,819,480	5,737,440
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of senior convertible preferred stock, net of issuance costs					$ 18
Balance at the ending at Jun. 30, 2020				$ 77,844	$ 50,192
Balance at the ending (in shares) at Jun. 30, 2020				9,819,480	5,737,440
Balance at the beginning at Mar. 31, 2020		5,123	(116,307)			(111,184)
Balance at the beginning (in shares) at Mar. 31, 2020	1,525,648
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense		201				201
Net loss			(4,705)			(4,705)
Balance at the ending at Jun. 30, 2020		5,324	(121,012)			(115,688)
Balance at the ending (in shares) at Jun. 30, 2020	1,525,648
Balance at the beginning at Dec. 31, 2020				$ 77,844	$ 50,192
Balance at the beginning (in shares) at Dec. 31, 2020				9,819,480	5,737,440
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of senior convertible preferred stock, net of issuance costs					$ 60,307
Issuance of senior convertible preferred stock, net of issuance costs (in shares)					4,938,482
Balance at the ending at Mar. 31, 2021				$ 77,844	$ 110,499
Balance at the ending (in shares) at Mar. 31, 2021				9,819,480	10,675,922
Balance at the beginning at Dec. 31, 2020		5,889	(131,459)			(125,570)
Balance at the beginning (in shares) at Dec. 31, 2020	1,700,625
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Fair value of warrants to purchase common stock issued to investor		1,071				1,071
Issuance of common stock upon exercise of stock options		229				229
Issuance of common stock upon exercise of stock options (in shares)	281,458
Stock-based compensation expense		239				239
Net loss			(6,359)			(6,359)
Balance at the ending at Mar. 31, 2021		7,428	(137,818)			(130,390)
Balance at the ending (in shares) at Mar. 31, 2021	1,982,083
Balance at the beginning at Dec. 31, 2020				$ 77,844	$ 50,192
Balance at the beginning (in shares) at Dec. 31, 2020				9,819,480	5,737,440
Balance at the ending at Jun. 30, 2021				$ 77,844	$ 149,144
Balance at the ending (in shares) at Jun. 30, 2021				9,819,480	13,791,579
Balance at the beginning at Dec. 31, 2020		5,889	(131,459)			$ (125,570)
Balance at the beginning (in shares) at Dec. 31, 2020	1,700,625
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)						304,330
Net loss						$ (12,666)
Balance at the ending at Jun. 30, 2021		8,327	(144,125)			(135,798)
Balance at the ending (in shares) at Jun. 30, 2021	2,004,955
Balance at the beginning at Mar. 31, 2021				$ 77,844	$ 110,499
Balance at the beginning (in shares) at Mar. 31, 2021				9,819,480	10,675,922
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of senior convertible preferred stock, net of issuance costs					$ 38,645
Issuance of senior convertible preferred stock, net of issuance costs (in shares)					3,115,657
Balance at the ending at Jun. 30, 2021				$ 77,844	$ 149,144
Balance at the ending (in shares) at Jun. 30, 2021				9,819,480	13,791,579
Balance at the beginning at Mar. 31, 2021		7,428	(137,818)			(130,390)
Balance at the beginning (in shares) at Mar. 31, 2021	1,982,083
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options		35				35
Issuance of common stock upon exercise of stock options (in shares)	22,872
Stock-based compensation expense		864				864
Net loss			(6,307)			(6,307)
Balance at the ending at Jun. 30, 2021		$ 8,327	$ (144,125)			$ (135,798)
Balance at the ending (in shares) at Jun. 30, 2021	2,004,955

Condensed Statements of Conve_2

Condensed Statements of Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020
Series D Senior Convertible Preferred Stock
Issue price per share			$ 9.03	$ 9.03
Stock issuance costs			$ 0.5	$ 0.5
Series E Senior Convertible Preferred Stock
Issue price per share	$ 12.46	$ 12.46
Stock issuance costs	$ 0.1	$ 0.1

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (6,307)	$ (6,359)	$ (4,705)	$ (4,696)	$ (12,666)	$ (9,401)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	200		200		378	457
Stock-based compensation					1,103	336
Non-cash interest expense					158	707
Gain on extinguishment of PPP loan	(1,050)				(1,050)	0
Other non-cash loss					9	5
Changes in operating assets and liabilities:
Accounts receivable					(12)	0
Prepaid expenses and other assets					(309)	(47)
Accounts payable					197	(282)
Deferred rent					61	54
Accrued and other current liabilities					935	481
Net cash used in operating activities					(13,188)	(8,760)
Cash flows from investing activities
Purchases of property and equipment					(126)	(22)
Net cash used in investing activities					(126)	(22)
Cash flows from financing activities
Proceeds allocated to issuance of common stock warrants					1,071	0
Proceeds from exercise of stock options					264	1
Proceeds from loan payable					0	1,050
Payment of convertible notes payable					(4,494)	(667)
Payment of loan payable					(3,100)	0
Capital lease principal payments					(34)	(52)
Payment of deferred offering costs					(2,133)	0
Net cash provided by financing activities					90,632	11,018
Net increase in cash and cash equivalents					77,318	2,236
Cash and cash equivalents at beginning of period		$ 13,533		$ 21,390	13,533	21,390	$ 21,390
Cash and cash equivalents at end of period	$ 90,851		$ 23,626		90,851	23,626	$ 13,533
Supplemental disclosure of cash flow information
Cash paid for interest					1,270	150
Supplemental disclosure of non-cash investing and financing information
Deferred offering costs included in accounts payable and accrued liabilities					618	0
Purchases of property and equipment in accounts payable and accruals					149	57
Series E senior convertible preferred stock offering costs included in accounts payable and accrued liabilities					80	0
Series E senior convertible preferred stock offering costs prepaid and deferred in prior period and reclassified to Series E senior convertible preferred stock					26	0
Series D Senior Convertible Preferred Stock
Cash flows from financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs					0	10,686
Series E Senior Convertible Preferred Stock
Cash flows from financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs					$ 99,058	$ 0

Description of Business and Fin

Description of Business and Financial Condition	6 Months Ended
Description of Business and Financial Condition	Jun. 30, 2021
Description of Business and Financial Condition
Description of Business and Financial Condition	1. Description of Business and Financial Condition Sera Prognostics, Inc. (the “Company”) is a women’s health diagnostic company utilizing its proprietary proteomics and bioinformatics platform to discover, develop and commercialize biomarker tests with an initial focus on improving pregnancy outcomes. The Company was incorporated in the State of Delaware on January 17, 2008 and its operations are located in Salt Lake City, Utah, including a Clinical Laboratory Improvement Amendments (“CLIA”)-certified laboratory. Since its inception, the Company’s activities have consisted of performing research and development, conducting clinical studies, acquiring product rights, raising capital, establishing facilities, and establishing commercial operations to market the PreTRM test. Liquidity and Capital Resources The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred net losses and negative cash flows from operations since inception and had an accumulated deficit of $144.1 million as of June 30, 2021. The Company’s management expects the Company to incur significant additional operating losses and negative cash flows for the foreseeable future, principally as a result of the Company’s commercialization activities for the PreTRM test, and to support additional clinical and preclinical trials and anticipated research and development activities. The Company had no significant commercial product revenue for the three and six months ended June 30, 2021 and has no recurring sources of licensing or other revenue. There can be no assurance that the Company will eventually achieve significant revenues or profitability to sustain operations, or if achieved, can sustain either on a continuing basis. If the Company is unable to achieve significant revenues or raise additional funds, when needed, it may not be able to continue the development or commercialization of its diagnostic products and could be required to delay, scale back or abandon some or all of its development programs and other operations. No assurance can be given that the Company will be successful in raising the required capital on reasonable terms and at the required times, or at all. Any additional equity financing, if available to the Company, may not be available on favorable terms and may be dilutive to current stockholders, and any debt financing, if available, may involve restrictive covenants and dilutive financing instruments. The Company’s future operations are highly dependent on a combination of factors, including (i) the successful commercial launch and market acceptance of the PreTRM test; (ii) the success of clinical trials and other research and development programs; (iii) the development of competitive products by other biotechnology and laboratory companies; (iv) the Company’s ability to manage growth of the organization; (v) the Company’s ability to protect its intellectual property, technology and products; and, ultimately (vi) the timely and successful completion of any additional financing. The principal sources of the Company’s working capital to date have been the proceeds from the issuance of convertible preferred stock, convertible notes, and bank loans. As of June 30, 2021, the Company had approximately $90.9 million in cash and cash equivalents. In July 2021, the Company completed its initial public offering (“IPO”) of shares of Class A common stock. See Note 14—Subsequent Events for additional details. The Company believes that its existing financial resources are sufficient to continue operating activities at least 12 months from the issuance date of these unaudited condensed financial statements.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
Significant Accounting Policies	Jun. 30, 2021
Significant Accounting Policies
Significant Accounting Policies	2. Significant Accounting Policies There have been no significant changes to the Company’s significant accounting policies during the three and six months ended June 30, 2021 as compared to the significant accounting policies described in Note 2 of the “Notes to Financial Statements” in the Company’s audited financial statements included in its final prospectus dated as of July 14, 2021 and filed with the Securities and Exchange Commission (“SEC”) pursuant to Rule 424(b)(4) on July 16, 2021 (“Final Prospectus”). Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, these unaudited condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes as of and for the year ended December 31, 2020 included in the Final Prospectus. The unaudited interim condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2020, and, in the opinion of the Company’s management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial results. The results of the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other period. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification (“ASC”), and Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). Reverse Stock Split On June 30, 2021, the Company’s board of directors (the “Board of Directors”) approved a 1-for-2.079 Use of Estimates The preparation of the condensed financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, including those related to the determination of fair value of its shares of common stock and stock options, common and preferred stock warrants, valuation of deferred tax assets resulting from net operating losses, and useful lives of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates. The COVID-19 pandemic and the rapidly evolving actions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. The extent to which the COVID-19 pandemic may impact the Company’s business, financial condition, cash flows and results of operations, in particular, will depend on future developments that are highly uncertain, many of which are outside the Company’s control. Such developments include the availability and effectiveness of actions taken to contain or treat COVID-19, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company’s business, financial condition, cash flows and results of operations. There were no significant estimates contained in the preparation of the Company’s condensed financial statements or impacts to the Company’s condensed financial statements for the three and six months ended June 30, 2021 that were a direct result of the COVID-19 pandemic. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of the condensed financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by the Company’s management to, have a material impact on the Company’s financial position, results of operations or cash flows.

Property and Equipment

Property and Equipment	6 Months Ended
Property and Equipment	Jun. 30, 2021
Property and Equipment
Property and Equipment	3. Property and Equipment The following table presents the components of property and equipment, net, as of June 30, 2021 and December 31, 2020 (in thousands): June 30, December 31, 2021 2020 Laboratory equipment $ 4,241 $ 4,194 Computer equipment 951 767 Leasehold improvements 701 701 Software 373 373 Furniture and fixtures 292 292 Total property and equipment 6,558 6,327 Less accumulated depreciation and amortization (5,687) (5,362) Property and equipment, net $ 871 $ 965 As of June 30, 2021 and December 31, 2020, $3.0 million of the Company’s laboratory equipment was subject to capital leases, which assets had recorded accumulated amortization of $2.9 million and $2.6 million, respectively. Associated amortization expense, included with depreciation expense, for the three months ended June 30, 2021 and June 30, 2020 totaled $0.1 million each. Associated amortization expense for the six months ended June 30, 2021 and June 30, 2020 totaled $0.2 million and $0.3 million, respectively. Depreciation and amortization expense was $0.2 million for the three months ended June 30, 2021 and 2020. Depreciation and amortization expense was $0.4 million and $0.5 million for the six months ended June 30, 2021 and 2020, respectively.

Accrued and Other Current Liabi

Accrued and Other Current Liabilities	6 Months Ended
Accrued and Other Current Liabilities	Jun. 30, 2021
Accrued and Other Current Liabilities
Accrued and Other Current Liabilities	4. Accrued and Other Current Liabilities The following table presents the components of accrued and other current liabilities as of June 30, 2021 and December 31, 2020 (in thousands): June 30, December 31, 2021 2020 Accrued compensation $ 903 $ 996 Accrued paid time off 550 290 Accrued invoices related to IPO 379 — Bank loan final payment fee — 100 Other current liabilities 165 191 Total accrued and other current liabilities $ 1,997 $ 1,577

Other Income (Expense), net

Other Income (Expense), net	6 Months Ended
Other Income (Expense), net	Jun. 30, 2021
Other Income (Expense), net
Other Income (Expense), net	5. Other Income (Expense), net The following table presents the components of other income (expense), net, for the three and six months ended June 30, 2021 and 2020 (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Interest income $ 18 $ 6 $ 21 $ 34 Fair Value remeasurements 4 (10) (6) (5) Gain on extinguishment of PPP loan 1,050 — 1,050 — Other gains (losses), net — — (19) — Other income (expense), net $ 1,072 $ (4) $ 1,046 $ 29

Loans and Convertible Promissor

Loans and Convertible Promissory Notes Bank Loan	6 Months Ended
Loans and Convertible Promissory Notes Bank Loan	Jun. 30, 2021
Loans and Convertible Promissory Notes Bank Loan
Loans and Convertible Promissory Notes Bank Loan	6. Loans and Convertible Promissory Notes Bank Loan Bank Loan In 2014, through a Loan and Security Agreement (the “Loan Agreement”) with Pacific Western Bank (the “Bank”) the Company obtained a term loan for $10.0 million. The Loan Agreement, as amended, had a final repayment date of September 1, 2021. Repayment of amounts borrowed were paid in equal monthly installments of principal, plus all accrued interest. The loan bore interest, on the outstanding daily balance, equal to the greater of 1.0% above the Prime Rate then in effect, or 4.75%. In addition, the Loan Agreement required a Final Payment Fee (as defined in the Loan Agreement) equal to one-percent of the aggregate principal amount borrowed, or $0.1 million. In March 2021, the Company repaid the outstanding principal of $2.0 million, accrued interest of $6 thousand, and the Final Payment Fee of $0.1 million related to this loan. Convertible Promissory Notes In February 2019, the Company authorized the issuance of a $6.4 million subordinated convertible promissory note (the “February 2019 Convertible Note”) to a current stockholder, bearing 12% interest and a maturity date of February 26, 2021, to provide liquidity and additional working capital. On February 15, 2021, the maturity date was extended to March 28, 2021. The February 2019 Convertible Note was optionally convertible into shares of Series D Convertible Preferred Stock at a conversion price equal to 80% of the issuance price of the Series D Convertible Preferred Stock. In July 2019, $1.9 million of the $6.4 million February 2019 Convertible Note’s principal and $0.1 million of accrued interest were converted into 277,507 shares of the Company’s Series D Preferred Stock, at the option of the holder of the February 2019 Convertible Note, at a conversion price equal to 80% of the issuance price of the Series D Convertible Preferred Stock of $9.03 per share. If not repaid or converted prior to the maturity date, the February 2019 Convertible Note’s remaining principal and accrued interest would have converted, at the option of the Holder, into shares of Series C-1 Convertible Preferred Stock and the holder would have received a number of common stock warrants based on the amount of unpaid principal outstanding. The conversion feature of the February 2019 Convertible Note met the requirements for separate accounting and was recognized as a liability at the measurement date fair value of $2.4 million, subject to remeasurement to fair value, with any changes in estimated fair value recognized as a component of other income (expense), net. A corresponding discount, which reduced the carrying value of the February 2019 Convertible Note, was also recorded. The unamortized discount was written off in proportion to the partial conversion, with the remaining discount accreted to interest expense until maturity. The Company recognized additional interest expense of $0.1 million and $0.4 million from accretion of the discount during the six months ended June 30, 2021 and 2020, respectively. On March 24, 2021, the Company repaid the outstanding principal of $4.5 million and accrued interest of $1.1 million related to the February 2019 Convertible Note. In August 2019, the Company authorized the issuance of a $5.0 million subordinated convertible promissory note (the “August 2019 Note”) to a new investor and non-U.S. commercial partner. The August 2019 Note bore 5% interest and had a maturity date of December 31, 2019. The August 2019 Note was mandatorily convertible into shares of Series D Convertible Preferred Stock with principal and all interest accrued thereon converting at a per share price equal to the price per share at which Series D Convertible Preferred Stock was sold to investors. In August 2019, the August 2019 Note legally converted. Pursuant to the terms of a letter agreement, dated May 10, 2019, by and between the Company and the holder of the August 2019 Note, the holder is entitled to purchase additional shares of Series D Convertible Preferred Stock, in the event that a milestone, as defined in the agreement and within the Company’s control, is achieved. As of June 30, 2021, this milestone has not been achieved. Paycheck Protection Loan In April 2020, the Company obtained a $1.1 million loan through Pacific Western Bank under the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), as amended. The loan’s purpose was to maintain payroll and make rent and utilities payments as specified under the terms of the PPP. Under the PPP, borrowers may apply for loan forgiveness if the funds are used for payroll costs, mortgage interest, rent and utilities payments over a specified term following receipt of the loan funds. During the term of the agreement, the Company utilized the loan funds for forgivable purposes and applied for forgiveness. On June 26, 2021, the outstanding $1.1 million PPP loan was forgiven and removed from the Company’s balance sheet as of June 30, 2021. As a result of the forgiveness of the PPP loan, a $1.1 million gain on extinguishment was recorded in other income (expense), net for the three and six months ended June 30, 2021.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Jun. 30, 2021
Fair Value Measurements
Fair Value Measurements	7. Fair Value Measurements As of June 30, 2021 and December 31, 2020, the carrying amounts of the Company’s receivables, prepaid and other current assets, accounts payable, and accrued and other current liabilities approximate their fair values, principally due to the short-term nature of the assets and liabilities. The recorded values of the loan payable and capital leases approximate fair value as the interest rates approximate market interest rates. The fair value of the preferred stock warrant liability was estimated based upon a Black-Scholes option pricing model. The Company measures certain financial assets and liabilities (cash equivalents and the warrant liability) at fair value on a recurring basis. The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows: Level 1 inputs are observable, quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. Level 2 inputs are observable inputs other than quoted prices included in Level 1 that are observable either directly or indirectly or quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 inputs are unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions. As of June 30, 2021, the Company’s cash equivalents have been classified as Level 1 assets. The Company’s convertible preferred stock warrant liability has been valued using Level 3 inputs in a Black-Scholes option pricing model (see Note 11 — Warrants). The Company, utilizing a third-party valuation firm to assist with the estimation of the fair value of common stock, employed a hybrid method of option-pricing model (OPM) and Probability-Weighted Expected Return Method (“PWERM”). Under the hybrid OPM and PWERM approach, the per share value calculated under OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share of the common stock before a discount for lack of marketability is applied. This model also calculates the fair value of the other classes of equity, including preferred shares. This estimated preferred stock value, along with other significant unobservable inputs, was an input into a Black-Scholes option pricing model, which calculated the fair value of the preferred stock warrant liability. The other significant unobservable inputs in this calculation are the remaining expected term, which considers the timing of a liquidation event that would net settle the awards before their contractual term expires, and the expected equity volatility, which is a statistical measure of the dispersion of returns for a given security. Volatility is determined based on select comparable public guideline companies in the same business sector. The following table summarizes the significant unobservable inputs used to value the Company’s preferred stock warrant liability: As of June 30, 2021 As of December 31, 2020 Weighted- Weighted- Range Average Range Average Fair value per share of common stock $3.56 - $7.48 $ 4.70 $3.41 - $7.35 $ 4.56 Expected term (in years) 1.2 - 8.6 4.8 1.7 - 9.1 5.3 Expected volatility 60.3% - 67.6 % 63.6 % 59.5% - 72.5 % 63.6 % Significant increases (decreases) in the term would result in significantly higher (lower) fair value measurements. Significant increases (decreases) in the volatility would result in significantly higher (lower) fair value measurements. The following table shows the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands) as of June 30, 2021: Level 1 Level 2 Level 3 Assets: Cash equivalents $ 90,851 $ — $ — Liabilities: Warrant liability — — 485 Total $ 90,851 $ — $ 485 The following table shows the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands) as of December 31, 2020: Level 1 Level 2 Level 3 Assets: Cash equivalents $ 13,533 $ — $ — Liabilities: Warrant liability — — 474 Total $ 13,533 $ — $ 474 A table providing a roll forward of the fair value, as determined by Level 3 inputs, of the Company’s convertible preferred stock warrant liability for the six months ended June 30, 2021 is included in Note 11 — Warrants.

Related Party Transactions

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2021
Related Party Transactions
Related Party Transactions	8. Related Party Transactions In January 2017, Laboratory Corporation of America (“LabCorp”) and the Company entered into a strategic commercialization agreement contemporaneously with LabCorp’s participation in the Company’s sale of Series C Convertible Preferred Stock, par value $0.0001 per share. Under the agreement with LabCorp, amended in 2018, LabCorp is a non-exclusive distributor of the PreTRM test and performs certain sample collection, processing and shipping services, for a fee. The Company paid fees related to this agreement of less than $0.1 million for each of the three and six-month periods ended June 30, 2021 and 2020. In July 2019, the Company entered into a consulting agreement with Blue Ox Healthcare Partners, LLC (“Blue Ox”) to advise the Company on development of strategies with the goal to obtain widespread insurance coverage for the PreTRM test. Contemporaneously with the consulting agreement, Blue Ox participated in the initial closing of the Series D Convertible Preferred Stock financing in July 2019 and appointed its designee to the Board of Directors. The Company paid consulting fees related to the consulting agreement of $0.2 million and $0.1 million for the three months ended June 30, 2021 and 2020, respectively, and $0.3 million and $0.2 million for the six months ended June 30, 2021 and 2020, respectively. In June 2019, the Company entered into a master services agreement with Healthcore Inc., a wholly-owned subsidiary of Anthem Inc. (“Anthem”). This agreement covers a range of research projects, including Healthcore’s role as a contract research organization for the P R I ME In February 2021, the Company entered into a Commercial Collaboration Agreement with Anthem and its affiliates (the “Commercial Collaboration Agreement”). The Commercial Collaboration Agreement provides defined reimbursement within a defined period for use of the PreTRM test within Anthem’s network of covered members. Pursuant to the Commercial Collaboration Agreement, Anthem will purchase a certain minimum number of tests for each of the first three years of the term of the Commercial Collaboration Agreement. Additionally, Anthem has agreed to pay a certain minimum amount per year for the first three years of the term of the Commercial Collaboration Agreement. The Company has also agreed to develop a sales, marketing, and customer service program, and to provide training and marketing to duly licensed physicians specializing in obstetrics and gynecology or family medicine, or licensed nurse midwives, at the reasonable request of Anthem. Anthem has further agreed to develop appropriate care management programs that incorporate the use of the PreTRM test. The Company and Anthem have also agreed to form a Joint Operating Committee to oversee the relationship, comprised of two voting members each from Anthem and the Company. The Company will submit monthly invoices to Anthem for the sale of the PreTRM test at the negotiated rates. Anthem has been participating in the Company’s PRIME study and at the conclusion of the PRIME study, under the Commercial Collaboration Agreement, the Company has agreed to enter into Anthem’s standard lab provider agreement. Unless earlier terminated due to breach, the Commercial Collaboration Agreement will remain in effect until the later of (a) the third anniversary of the effective date or (b) the date on which Anthem has purchased a fixed number of PreTRM tests as agreed by the parties. The Commercial Collaboration Agreement with Anthem is considered to be within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”), as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company determined the PreTRM tests to be a performance obligation for which Anthem is a customer and a unit of account within the scope of ASC 606. The associated transaction price is based on the contractual minimum number of tests and the agreed upon defined reimbursement amount per test. The transaction price was allocated to this single performance obligation, which will be recognized upon delivery of test results expected to occur over the term of the agreement. All other items promised to Anthem are immaterial in the context of the Commercial Collaboration Agreement. There were no material revenues or cash receipts related to the Commercial Collaboration Agreement for the three and six months ended June 30, 2021.

Capital Structure

Capital Structure	6 Months Ended
Capital Structure	Jun. 30, 2021
Capital Structure
Capital Structure	9. Capital Structure Common Stock The following shares of Class A common stock were reserved for future issuance: June 30, 2021 December 31, 2020 Senior convertible preferred stock 13,791,579 5,737,440 Junior convertible preferred stock 9,819,480 9,819,480 Shares issuable under convertible note — 665,699 Warrants to purchase convertible preferred stock 81,543 81,543 Warrants to purchase Class A common stock 2,741,813 2,019,590 Options to purchase Class A common stock 5,677,611 4,096,722 Class A common stock available for future issuance under the 2011 Equity Incentive Plan 668,772 388,505 Total 32,780,798 22,808,979 As of June 30, 2021 and December 31, 2020, approximately $2.8 million and $26 thousand of deferred offering costs related to an equity offering, respectively, were recorded within other assets in the accompanying condensed balance sheets. Convertible Preferred Stock Authorized, issued and outstanding convertible preferred stock and its principal terms as of June 30, 2021 were as follows (in thousands, except share and per share amounts): Shares Issued Original Aggregate Proceeds, Shares and Issue Price Liquidation net of Series Authorized Outstanding Per Share Preference issuance costs Series A-1 Junior Preferred Stock 1,390 667 $ 2,079.00 $ 1,390 $ 1,390 Series A-2 Junior Preferred Stock 7,941,499 3,803,878 5.20 19,771 19,595 Series B-1 Junior Preferred Stock 2,060,000 961,994 5.20 5,000 4,914 Series B-2 Junior Preferred Stock 5,012,500 2,404,995 8.32 20,000 19,984 Series C-1 Junior Preferred Stock 5,521,905 2,647,946 12.38 32,755 32,653 Series C-2 Junior Preferred Stock 1,510,000 — 17.22 — — Series D Senior Preferred Stock 11,975,172 5,737,440 9.03 102,535 50,415 Series E Senior Preferred Stock 17,529,215 8,054,139 12.46 100,300 98,952 Total Convertible Preferred Stock 51,551,681 23,611,059 $ 281,751 $ 227,903 Authorized, issued and outstanding convertible preferred stock and its principal terms as of December 31, 2020 were as follows (in thousands, except share and per share amounts): Shares Issued Original Aggregate Proceeds, Shares and Issue Price Liquidation net of Series Authorized Outstanding Per Share Preference issuance costs Series A-1 Junior Preferred Stock 1,390 667 $ 2,079.00 $ 1,390 $ 1,390 Series A-2 Junior Preferred Stock 7,941,499 3,803,878 5.20 19,771 19,595 Series B-1 Junior Preferred Stock 2,060,000 961,994 5.20 5,000 4,914 Series B-2 Junior Preferred Stock 5,012,500 2,404,995 8.32 20,000 19,984 Series C-1 Junior Preferred Stock 5,521,905 2,647,946 12.38 32,755 32,653 Series C-2 Junior Preferred Stock 1,510,000 — 17.22 — — Series D Senior Preferred Stock 12,320,844 5,737,440 9.03 102,535 50,415 Total Convertible Preferred Stock 34,368,138 15,556,920 $ 181,451 $ 128,951 In connection with various preferred stock financings, the Company issued warrants to purchase common stock and warrants to purchase preferred stock. See Note 11 — Warrants for additional details. Conversion Rights Each outstanding share of convertible preferred stock is convertible, at the option of the holder at any time and from time to time, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the respective original issue price of the convertible preferred stock, as applicable, by the respective conversion price of the convertible preferred stock, as applicable, in effect at the time of the conversion. Conversion of all shares of convertible preferred stock is automatic upon (i) the closing of a public offering of common stock at a price per share of at least 1.2 times the original issue price of the Series E Convertible Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock) resulting in at least $40.0 million of gross cash proceeds; or (ii) affirmative election of at least a majority of the shares of preferred stock outstanding. As of June 30, 2021 and December 31, 2020, the conversion price of the Convertible Preferred Stock issued by the Company was as follows: Series June 30, 2021 December 31, 2020 Series A-1 Junior Preferred Stock $ 6.08 $ 6.08 Series A-2 Junior Preferred Stock 5.20 5.20 Series B-1 Junior Preferred Stock 5.20 5.20 Series B-2 Junior Preferred Stock 8.32 8.32 Series C-1 Junior Preferred Stock 12.38 12.38 Series C-2 Junior Preferred Stock 17.22 17.22 Series D Senior Preferred Stock 9.03 9.03 Series E Senior Preferred Stock 12.46 — In July 2021, the Company completed its IPO. In connection with the IPO, all shares of convertible preferred stock converted into 22,434,130 shares of Class A common stock and 1,405,259 shares of Class B common stock. See Note 14—Subsequent Events.

Stock-based Compensation

Stock-based Compensation	6 Months Ended
Stock-based Compensation	Jun. 30, 2021
Stock-based Compensation
Stock-based Compensation	10. Stock-based Compensation Equity Incentive Plans In November 2011, the Company established the 2011 Employee, Director and Consultant Equity Incentive Plan (the “2011 Plan”) and reserved shares of the Company’s common stock for sale and issuance under the 2011 Plan. The 2011 Plan provides for the grant of incentive and non-statutory stock options as well as restricted stock to employees, nonemployee directors and consultants of the Company, which are to be granted at a price that is not less than 100% of the fair value of the stock at the date of grant. Options and restricted stock generally vest over a four The 2021 Equity Incentive Plan (the “2021 Plan”) was adopted by the Board of Directors on June 30, 2021, approved by the Company’s stockholders in July 2021 and became effective in connection with the closing of the IPO. A total of 3,966,162 shares of Class A common stock have been reserved for issuance under the 2021 Plan. The number of shares of Class A common stock reserved for issuance under the 2021 Plan will also be increased pursuant to provisions for annual automatic evergreen increases. The 2021 Employee Stock Purchase Plan (the “2021 ESPP”) was adopted by the Board of Directors on June 30, 2021, approved by the Company’s stockholders in July 2021 and became effective in connection with the closing of the IPO. A total of 305,089 shares of Class A common stock have been reserved for issuance under the 2021 ESPP. In addition, the number of shares reserved for future issuance under the 2021 ESPP will be increased pursuant to provisions for annual automatic evergreen increases. Stock Options Unless otherwise noted, references to “options” in the subsequent disclosures, refers to the combined incentive and non-statutory stock options issued as employee and non-employee stock-based compensation, and authorized under the 2008 Plan and 2011 Plan. The following table summarizes information about these options granted and outstanding: Number of Weighted- Shares Weighted- Weighted- Average Subject to Average Average Remaining Options Grant Date Exercise Price Contractual Outstanding Fair Value Per Share Life (In Years) Outstanding — December 31, 2020 4,096,722 $ 0.92 $ 1.64 6.99 Granted 1,885,456 5.54 6.72 Expired (63) 131.73 207.90 Cancelled (174) 1.04 1.98 Exercised (304,330) 0.55 0.87 Outstanding — June 30, 2021 5,677,611 $ 2.47 $ 3.37 7.81 Vested and expected to vest at June 30, 2021 5,351,674 $ 2.37 $ 3.26 7.71 Vested and exercisable at June 30, 2021 2,564,974 $ 1.11 $ 1.83 6.00 Non-vested options at June 30, 2021 3,112,538 $ 3.59 $ 4.63 The following table presents the impact of stock-based compensation expense in the statements of operations for the periods indicated (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Research and development expense $ 370 $ 69 $ 434 $ 123 Sales and marketing expense 117 35 179 64 General and administrative expense 377 97 490 149 Total employee stock-based compensation $ 864 $ 201 $ 1,103 $ 336 At June 30, 2021, there was $9.5 million of unamortized stock-based compensation cost related to unvested stock options which is expected to be recognized over a weighted average period of 3.4 years.

Warrants

Warrants	6 Months Ended
Warrants	Jun. 30, 2021
Warrants
Warrants	11. Warrants Warrants to purchase common stock In conjunction with the issuance of Series D Convertible Preferred Stock, the Company issued 1,009,795 warrants to purchase shares of common stock at a price of $9.03 per share, and 1,009,795 warrants to purchase shares of common stock at a price of $10.84 per share. Because these warrants are equity classified, the Company allocated the relative fair value of the cash proceeds between the Series D Convertible Preferred Stock and the warrants. Proceeds allocated to these common stock warrants on a relative fair value basis, calculated using the Black-Scholes option pricing model, were $0.9 million and were recognized as a component of additional paid-in capital in the accompanying condensed financial statements. As an equity instrument, these warrants are not required to be remeasured to their fair value each reporting period. A certain investor of Series E Convertible Preferred Stock also received 722,223 warrants to purchase shares of common stock of the Company at a price of $20.77 per share. Because these warrants are equity classified, the Company allocated the relative fair value of the cash proceeds between the Series E Convertible Preferred Stock and the warrants. Proceeds allocated to these common stock warrants on a relative fair value basis, calculated using the Black-Scholes option pricing model, were $1.1 million and were recognized as a component of additional paid-in capital in the accompanying condensed financial statements. As an equity instrument, these warrants are not required to be remeasured to their fair value each reporting period. Warrants to purchase preferred stock In conjunction with the issuance of Series D Convertible Preferred Stock, the Company issued a third-party consultant a fully-vested warrant to purchase 21,611 shares (the “2019 Warrant”) of Series D Convertible Preferred Stock at a price of $9.03 per share. The initial fair value of the 2019 Warrant was calculated using the Black-Scholes option pricing model and recorded as a reduction in additional paid-in capital associated with Series D Preferred Stock Financing. The 2019 Warrant, which increased to 22,609 shares in conjunction with the issuance of additional shares of Series D Convertible Preferred Stock in 2020, remains outstanding at June 30, 2021, and is immediately exercisable for cash, with 22,609 shares to be issued upon settlement of the 2019 Warrant. The Company paid fees of $0.4 million to this consultant and the estimated fair value of the warrants was $0.2 million. The Company recognized the fees and the fair value of the warrants issued as a reduction to additional paid-in capital and recorded a corresponding preferred stock warrant liability. Total adjustments to the fair value of this warrant liability resulted in other income of $4 thousand and other expense of $10 thousand during the three months ended June 30, 2021 and 2020, respectively. Total adjustments to the fair value of this warrant liability resulted in other expense of $6 thousand and $5 thousand during the six months ended June 30, 2021 and 2020, respectively. In connection with various debt financings, refinancing, and amendments to the Loan Agreement with the Bank, the Company has, from time to time, issued warrants to purchase shares of convertible preferred stock. Each of these warrants are exercisable for cash, fully-vested at the grant date, and have a ten-year expiration. The initial fair value of each these warrants was calculated using the Black-Scholes option pricing model and recorded as a reduction to the carrying value of the bank loan payable in the year of issuance. During the fiscal year, any changes in the fair value of these warrant liabilities are recorded in interest expense. Total adjustments to the fair value of these warrant liabilities during the three months ended June 30, 2021 and 2020 resulted in a $5 thousand reduction of interest expense and a $4 thousand reduction of interest expense, respectively. Total adjustments to the fair value of these warrant liabilities during the six months ended June 30, 2021 and 2020 resulted in $5 thousand of interest expense and a $4 thousand reduction of interest expense, respectively. The following table summarizes the warrants to purchase convertible preferred stock and the fair value as of June 30, 2021 and December 31, 2020 (in thousands, except share and per share amounts): Fair Value as of Number of Exercise June 30, December 31, Series Grant Date Warrants Price 2021 2020 Series A-2 Sep 2012 12,506 $ 5.20 $ 37 $ 41 Series A-2 Sep 2014 3,473 5.20 14 13 Series B-1 Dec 2014 28,860 5.20 120 113 Series B-2 Dec 2015 6,012 8.32 23 22 Series C-1 Mar 8,083 12.38 31 31 Series D Feb 2020 22,609 9.03 260 254 Total 81,543 $ 485 $ 474 Liability classification requires the warrants to be remeasured to their fair value at each reporting period. As of June 30, 2021 and December 31, 2020, the fair value of preferred stock warrants outstanding was $0.5 million and was recorded in warrant liability as a long-term liability in the accompanying condensed balance sheets. The following is a summary of the Company’s preferred stock warrant liability activity for the six months ended June 30, 2021 (in thousands): Warrant Liability Outstanding Outstanding — December 31, 2020 $ 474 Net increase in fair value of preferred stock warrants — recognized in other income (expense), net 6 Net increase in fair value of preferred stock warrants — recognized in interest expense 5 Outstanding — June 30, 2021 $ 485

Commitments and Contingences

Commitments and Contingences	6 Months Ended
Commitments and Contingences	Jun. 30, 2021
Commitments and Contingences
Commitments and Contingences	12. Commitments and Contingences Operating Leases The Company leases a total of approximately 24,100 square feet of office and laboratory space under a single non-cancelable operating lease with a termination date of December 31, 2022. Under the terms of the lease agreement, the Company has an option to renew the lease for one additional five-year rental period. The lease included a tenant improvement allowance from the landlord for structural and cosmetic changes to the new space. The tenant improvements were completed and delivery of possession occurred on September 1, 2018. The tenant improvement allowance has been accounted for as a liability of the Company within deferred rent and is amortized monthly as a reduction to rent expense. A corresponding leasehold improvement asset has been recorded with monthly depreciation being recorded as depreciation expense. Scheduled base rent increases of 3% occur annually each August. The Company recognizes rent expense on a straight-line basis over the term of the operating lease. The difference in actual amounts paid and amounts recorded as rent expense during the period was recorded as deferred rent on the accompanying balance sheets. For the three months ended June 30, 2021 and 2020, the Company recognized rent expense of $0.1 million. For the six months ended June 30, 2021 and 2020, the Company recognized rent expense of $0.3 million. Amounts classified as deferred rent at June 30, 2021 and December 31, 2020 totaled $0.2 million and $0.3 million, respectively. Capital Leases The full value of all leased equipment, including advance payments, are classified as assets on the Company’s balance sheets. The portion of the future payments designated as principal repayment are classified as a capital lease obligation. As of June 30, 2021, the Company classified the aggregate amount of scheduled capital lease obligation payments due within twelve months of the date of the condensed financial statements, $0.1 million, as a current liability, and the remaining $0.1 million due thereafter, in other liabilities. Indemnification The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company’s request in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company purchases director and officer insurance coverage that provides for corporate reimbursements of covered obligations that limits the Company’s exposure and enables it to recover a portion of potential future amounts paid. The Company is unable to reasonably estimate the maximum amount that could be payable under these arrangements since these obligations are not capped but are conditional to the unique facts and circumstances involved. Accordingly, the Company has no liabilities recorded for these agreements as of June 30, 2021 and December 31, 2020. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. Employee Agreements The Company has signed various employment agreements with key executives pursuant to which if their employment is terminated by the Company without cause or by the employees for good reason, or following a change of control of the Company, the employees are entitled to receive certain benefits, including severance payments, accelerated vesting of stock and stock options, and certain insurance benefits. Legal Matters The Company is not currently a party to any material litigation or other material legal proceedings. The Company may, from time to time, be involved in various legal proceedings arising from the normal course of business activities, and an unfavorable resolution of any of these matters could materially affect the Company’s future results of operations, cash flows, or financial position.

Net loss per share

Net loss per share	6 Months Ended
Net loss per share	Jun. 30, 2021
Net loss per share
Net loss per share	13. Net loss per share The Company issued certain convertible preferred stock that were outstanding and were concluded to be participating securities. Due to the presence of participating securities, the Company calculated net loss per share using the more dilutive of the treasury stock or the two-class method. For periods presented in which the Company reports a net loss, the losses are not allocated to the participating securities. As the Company reported a net loss during all periods presented, diluted net loss per share was the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Net loss $ (6,307) $ (4,705) $ (12,666) $ (9,401) Weighted average common stock outstanding, basic and diluted 1,988,886 1,525,648 1,890,908 1,525,491 Net loss per share — basic and diluted $ (3.17) $ (3.08) $ (6.70) $ (6.16) The Company excluded the following potentially dilutive securities, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because their impact would have been anti-dilutive: June 30, 2021 2020 Junior convertible preferred stock 9,819,480 9,819,480 Senior convertible preferred stock 13,791,579 5,737,440 Shares issuable under convertible note — 632,733 Warrants to purchase convertible preferred stock 81,543 81,543 Warrants to purchase Class A common stock 2,741,813 2,019,590 Options to purchase Class A common stock 5,677,611 4,329,722 Total 32,112,026 22,620,508

Subsequent Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2021
Subsequent Events
Subsequent Events	14. Subsequent Events Initial Public Offering On July 19, 2021, the Company completed its IPO and issued 4,687,500 shares of its common stock at a price of $16.00 per share for approximate net proceeds of $66.6 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company. In connection with the IPO, all shares of convertible preferred stock converted into 22,434,130 shares of Class A common stock and 1,405,259 shares of Class B common stock.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2021
Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, these unaudited condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes as of and for the year ended December 31, 2020 included in the Final Prospectus. The unaudited interim condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2020, and, in the opinion of the Company’s management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial results. The results of the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other period. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification (“ASC”), and Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”).
Reverse Stock Split	Reverse Stock Split On June 30, 2021, the Company’s board of directors (the “Board of Directors”) approved a 1-for-2.079
Use of Estimates	Use of Estimates The preparation of the condensed financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, including those related to the determination of fair value of its shares of common stock and stock options, common and preferred stock warrants, valuation of deferred tax assets resulting from net operating losses, and useful lives of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates. The COVID-19 pandemic and the rapidly evolving actions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. The extent to which the COVID-19 pandemic may impact the Company’s business, financial condition, cash flows and results of operations, in particular, will depend on future developments that are highly uncertain, many of which are outside the Company’s control. Such developments include the availability and effectiveness of actions taken to contain or treat COVID-19, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company’s business, financial condition, cash flows and results of operations. There were no significant estimates contained in the preparation of the Company’s condensed financial statements or impacts to the Company’s condensed financial statements for the three and six months ended June 30, 2021 that were a direct result of the COVID-19 pandemic. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of the condensed financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by the Company’s management to, have a material impact on the Company’s financial position, results of operations or cash flows.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
Property and Equipment (Tables)	Jun. 30, 2021
Property and Equipment
Schedule of components of property and equipment, net	The following table presents the components of property and equipment, net, as of June 30, 2021 and December 31, 2020 (in thousands): June 30, December 31, 2021 2020 Laboratory equipment $ 4,241 $ 4,194 Computer equipment 951 767 Leasehold improvements 701 701 Software 373 373 Furniture and fixtures 292 292 Total property and equipment 6,558 6,327 Less accumulated depreciation and amortization (5,687) (5,362) Property and equipment, net $ 871 $ 965

Accrued and Other Current Lia_2

Accrued and Other Current Liabilities (Tables)	6 Months Ended
Accrued and Other Current Liabilities (Tables)	Jun. 30, 2021
Accrued and Other Current Liabilities
Schedule of components of accrued and other current liabilities	The following table presents the components of accrued and other current liabilities as of June 30, 2021 and December 31, 2020 (in thousands): June 30, December 31, 2021 2020 Accrued compensation $ 903 $ 996 Accrued paid time off 550 290 Accrued invoices related to IPO 379 — Bank loan final payment fee — 100 Other current liabilities 165 191 Total accrued and other current liabilities $ 1,997 $ 1,577

Other Income (Expense), net (Ta

Other Income (Expense), net (Tables)	6 Months Ended
Other Income (Expense), net (Tables)	Jun. 30, 2021
Other Income (Expense), net
Schedule of components of other income (expense), net	The following table presents the components of other income (expense), net, for the three and six months ended June 30, 2021 and 2020 (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Interest income $ 18 $ 6 $ 21 $ 34 Fair Value remeasurements 4 (10) (6) (5) Gain on extinguishment of PPP loan 1,050 — 1,050 — Other gains (losses), net — — (19) — Other income (expense), net $ 1,072 $ (4) $ 1,046 $ 29

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
Fair Value Measurements (Tables)	Jun. 30, 2021
Fair Value Measurements
Schedule of significant unobservable inputs used to value the preferred stock warrant liability	As of June 30, 2021 As of December 31, 2020 Weighted- Weighted- Range Average Range Average Fair value per share of common stock $3.56 - $7.48 $ 4.70 $3.41 - $7.35 $ 4.56 Expected term (in years) 1.2 - 8.6 4.8 1.7 - 9.1 5.3 Expected volatility 60.3% - 67.6 % 63.6 % 59.5% - 72.5 % 63.6 %
Schedule of financial assets that are measured at fair value on a recurring basis	The following table shows the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands) as of June 30, 2021: Level 1 Level 2 Level 3 Assets: Cash equivalents $ 90,851 $ — $ — Liabilities: Warrant liability — — 485 Total $ 90,851 $ — $ 485 The following table shows the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands) as of December 31, 2020: Level 1 Level 2 Level 3 Assets: Cash equivalents $ 13,533 $ — $ — Liabilities: Warrant liability — — 474 Total $ 13,533 $ — $ 474

Capital Structure (Tables)

Capital Structure (Tables)	6 Months Ended
Capital Structure (Tables)	Jun. 30, 2021
Capital Structure
Schedule of common stock reserved for future issuance	The following shares of Class A common stock were reserved for future issuance: June 30, 2021 December 31, 2020 Senior convertible preferred stock 13,791,579 5,737,440 Junior convertible preferred stock 9,819,480 9,819,480 Shares issuable under convertible note — 665,699 Warrants to purchase convertible preferred stock 81,543 81,543 Warrants to purchase Class A common stock 2,741,813 2,019,590 Options to purchase Class A common stock 5,677,611 4,096,722 Class A common stock available for future issuance under the 2011 Equity Incentive Plan 668,772 388,505 Total 32,780,798 22,808,979
Schedule of authorized, issued and outstanding convertible preferred stock and its principal terms	Authorized, issued and outstanding convertible preferred stock and its principal terms as of June 30, 2021 were as follows (in thousands, except share and per share amounts): Shares Issued Original Aggregate Proceeds, Shares and Issue Price Liquidation net of Series Authorized Outstanding Per Share Preference issuance costs Series A-1 Junior Preferred Stock 1,390 667 $ 2,079.00 $ 1,390 $ 1,390 Series A-2 Junior Preferred Stock 7,941,499 3,803,878 5.20 19,771 19,595 Series B-1 Junior Preferred Stock 2,060,000 961,994 5.20 5,000 4,914 Series B-2 Junior Preferred Stock 5,012,500 2,404,995 8.32 20,000 19,984 Series C-1 Junior Preferred Stock 5,521,905 2,647,946 12.38 32,755 32,653 Series C-2 Junior Preferred Stock 1,510,000 — 17.22 — — Series D Senior Preferred Stock 11,975,172 5,737,440 9.03 102,535 50,415 Series E Senior Preferred Stock 17,529,215 8,054,139 12.46 100,300 98,952 Total Convertible Preferred Stock 51,551,681 23,611,059 $ 281,751 $ 227,903 Authorized, issued and outstanding convertible preferred stock and its principal terms as of December 31, 2020 were as follows (in thousands, except share and per share amounts): Shares Issued Original Aggregate Proceeds, Shares and Issue Price Liquidation net of Series Authorized Outstanding Per Share Preference issuance costs Series A-1 Junior Preferred Stock 1,390 667 $ 2,079.00 $ 1,390 $ 1,390 Series A-2 Junior Preferred Stock 7,941,499 3,803,878 5.20 19,771 19,595 Series B-1 Junior Preferred Stock 2,060,000 961,994 5.20 5,000 4,914 Series B-2 Junior Preferred Stock 5,012,500 2,404,995 8.32 20,000 19,984 Series C-1 Junior Preferred Stock 5,521,905 2,647,946 12.38 32,755 32,653 Series C-2 Junior Preferred Stock 1,510,000 — 17.22 — — Series D Senior Preferred Stock 12,320,844 5,737,440 9.03 102,535 50,415 Total Convertible Preferred Stock 34,368,138 15,556,920 $ 181,451 $ 128,951
Schedule of conversion price of Convertible Preferred Stock	As of June 30, 2021 and December 31, 2020, the conversion price of the Convertible Preferred Stock issued by the Company was as follows: Series June 30, 2021 December 31, 2020 Series A-1 Junior Preferred Stock $ 6.08 $ 6.08 Series A-2 Junior Preferred Stock 5.20 5.20 Series B-1 Junior Preferred Stock 5.20 5.20 Series B-2 Junior Preferred Stock 8.32 8.32 Series C-1 Junior Preferred Stock 12.38 12.38 Series C-2 Junior Preferred Stock 17.22 17.22 Series D Senior Preferred Stock 9.03 9.03 Series E Senior Preferred Stock 12.46 —

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
Stock-based Compensation (Tables)	Jun. 30, 2021
Stock-based Compensation
Schedule of stock options activity	Number of Weighted- Shares Weighted- Weighted- Average Subject to Average Average Remaining Options Grant Date Exercise Price Contractual Outstanding Fair Value Per Share Life (In Years) Outstanding — December 31, 2020 4,096,722 $ 0.92 $ 1.64 6.99 Granted 1,885,456 5.54 6.72 Expired (63) 131.73 207.90 Cancelled (174) 1.04 1.98 Exercised (304,330) 0.55 0.87 Outstanding — June 30, 2021 5,677,611 $ 2.47 $ 3.37 7.81 Vested and expected to vest at June 30, 2021 5,351,674 $ 2.37 $ 3.26 7.71 Vested and exercisable at June 30, 2021 2,564,974 $ 1.11 $ 1.83 6.00 Non-vested options at June 30, 2021 3,112,538 $ 3.59 $ 4.63
Schedule of impact of stock-based compensation expense in the statements of operations	The following table presents the impact of stock-based compensation expense in the statements of operations for the periods indicated (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Research and development expense $ 370 $ 69 $ 434 $ 123 Sales and marketing expense 117 35 179 64 General and administrative expense 377 97 490 149 Total employee stock-based compensation $ 864 $ 201 $ 1,103 $ 336

Warrants (Tables)

Warrants (Tables)	6 Months Ended
Warrants (Tables)	Jun. 30, 2021
Warrants
Schedule of warrants to purchase convertible preferred stock including fair value	The following table summarizes the warrants to purchase convertible preferred stock and the fair value as of June 30, 2021 and December 31, 2020 (in thousands, except share and per share amounts): Fair Value as of Number of Exercise June 30, December 31, Series Grant Date Warrants Price 2021 2020 Series A-2 Sep 2012 12,506 $ 5.20 $ 37 $ 41 Series A-2 Sep 2014 3,473 5.20 14 13 Series B-1 Dec 2014 28,860 5.20 120 113 Series B-2 Dec 2015 6,012 8.32 23 22 Series C-1 Mar 8,083 12.38 31 31 Series D Feb 2020 22,609 9.03 260 254 Total 81,543 $ 485 $ 474
Schedule of the preferred stock warrant liability activity	The following is a summary of the Company’s preferred stock warrant liability activity for the six months ended June 30, 2021 (in thousands): Warrant Liability Outstanding Outstanding — December 31, 2020 $ 474 Net increase in fair value of preferred stock warrants — recognized in other income (expense), net 6 Net increase in fair value of preferred stock warrants — recognized in interest expense 5 Outstanding — June 30, 2021 $ 485

Net loss per share (Tables)

Net loss per share (Tables)	6 Months Ended
Net loss per share (Tables)	Jun. 30, 2021
Net loss per share
Schedule of computation of basic and diluted net loss per share	The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts): Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Net loss $ (6,307) $ (4,705) $ (12,666) $ (9,401) Weighted average common stock outstanding, basic and diluted 1,988,886 1,525,648 1,890,908 1,525,491 Net loss per share — basic and diluted $ (3.17) $ (3.08) $ (6.70) $ (6.16)
Schedule of anti-dilutive securities excluded from the computation of earnings per share	The Company excluded the following potentially dilutive securities, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because their impact would have been anti-dilutive: June 30, 2021 2020 Junior convertible preferred stock 9,819,480 9,819,480 Senior convertible preferred stock 13,791,579 5,737,440 Shares issuable under convertible note — 632,733 Warrants to purchase convertible preferred stock 81,543 81,543 Warrants to purchase Class A common stock 2,741,813 2,019,590 Options to purchase Class A common stock 5,677,611 4,329,722 Total 32,112,026 22,620,508

Description of Business and F_2

Description of Business and Financial Condition (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Description of Business and Financial Condition
Accumulated deficit	$ (144,125)	$ (131,459)
Cash and cash equivalents	$ 90,851	$ 13,533

Significant Accounting Polici_3

Significant Accounting Policies (Details)	Jun. 30, 2021
Significant Accounting Policies
Stockholders' Equity Note, Stock Split, Conversion Ratio	0.48

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property and Equipment [Line Items]
Total property and equipment	$ 6,558	$ 6,327
Less accumulated depreciation and amortization	(5,687)	(5,362)
Property and equipment, net	871	965
Laboratory equipment
Property and Equipment [Line Items]
Total property and equipment	4,241	4,194
Computer equipment
Property and Equipment [Line Items]
Total property and equipment	951	767
Leasehold improvements
Property and Equipment [Line Items]
Total property and equipment	701	701
Software
Property and Equipment [Line Items]
Total property and equipment	373	373
Furniture and fixtures
Property and Equipment [Line Items]
Total property and equipment	$ 292	$ 292

Property and Equipment - Additi

Property and Equipment - Additional information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Property and Equipment [Line Items]
Depreciation and amortization	$ 200	$ 200	$ 378	$ 457
Laboratory equipment
Property and Equipment [Line Items]
Assets subject to capital leases	3,000		3,000		$ 3,000
Capital lease assets accumulated amortization	2,900		2,900		$ 2,600
Capital lease amortization expense	$ 100	$ 100	$ 200	$ 300

Accrued and Other Current Lia_3

Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accrued and Other Current Liabilities
Accrued compensation	$ 903	$ 996
Accrued paid time off	550	290
Accrued invoices related to IPO	379
Bank loan final payment fee		100
Other current liabilities	165	191
Total accrued and other current liabilities	$ 1,997	$ 1,577

Other Income (Expense), net (De

Other Income (Expense), net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Other Income (Expense), net
Interest income	$ 18	$ 6	$ 21	$ 34
Fair Value remeasurements	4	(10)	(6)	(5)
Gain on extinguishment of PPP loan	1,050		1,050	0
Other gains (losses), net			(19)
Other income (expense), net	$ 1,072	$ (4)	$ 1,046	$ 29

Loans and Convertible Promiss_2

Loans and Convertible Promissory Notes Bank Loan - Bank Loan (Details) - Loan and Security Agreement - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2014
Debt Instrument [Line Items]
Term Loan		$ 10,000
Long term debt, Interest rate		4.75%
Percentage of amount borrowed from bank loan		1.00%
Repayment of outstanding principal	$ 2,000
Repayment of accrued interest	6
Final payment fee	$ 100	$ 100
Prime Rate
Debt Instrument [Line Items]
Long term debt, spread on base interest rate		1.00%

Loans and Convertible Promiss_3

Loans and Convertible Promissory Notes Bank Loan - Convertible Promissory Notes (Details) $ / shares in Units, $ in Millions	Mar. 24, 2021USD ($)	Feb. 15, 2021	Jul. 31, 2019USD ($)$ / sharesshares	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Aug. 31, 2019USD ($)	Feb. 28, 2019USD ($)
Series D Convertible Preferred Stock
Debt Instrument [Line Items]
Debt instrument, conversion price percentage		80	80
February 2019 Convertible Note
Debt Instrument [Line Items]
Aggregate principal amount							$ 6.4
Repayment of outstanding principal	$ 4.5
Repayment of accrued interest	$ 1.1
Debt instrument, stated interest rate							12.00%
Interest expense			$ 0.1
Debt instrument, convertible, conversion price \| $ / shares			$ 9.03
Liability at the measurement date fair value				$ 2.4
Accretion of discount				$ 0.1	$ 0.4
February 2019 Convertible Note \| Series D Convertible Preferred Stock
Debt Instrument [Line Items]
Amount of original debt converted			$ 1.9
Debt conversion, converted instrument, shares issued \| shares			277,507
August 2019 Note
Debt Instrument [Line Items]
Aggregate principal amount						$ 5
Debt instrument, stated interest rate						5.00%

Loans and Convertible Promiss_4

Loans and Convertible Promissory Notes Bank Loan - Paycheck Protection Loan (Details) - USD ($) $ in Thousands	Jun. 26, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Apr. 30, 2020
Debt Instrument [Line Items]
Gain on extinguishment of PPP loan		$ 1,050	$ 1,050	$ 0
Paycheck Protection Program Loan
Debt Instrument [Line Items]
Aggregate principal amount					$ 1,100
Amount of debt forgiven	$ 1,100
Gain on extinguishment of PPP loan		$ 1,100	$ 1,100

Fair Value Measurements - Signi

Fair Value Measurements - Significant unobservable inputs (Details) - Level 3	Jun. 30, 2021$ / sharesUSD ($)	Dec. 31, 2020$ / sharesUSD ($)
Minimum \| Fair value per share of common stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input \| $ / shares	3.56	3.41
Minimum \| Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input \| $	1.2	1.7
Minimum \| Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	60.3	59.5
Maximum \| Fair value per share of common stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input \| $ / shares	7.48	7.35
Maximum \| Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input \| $	8.6	9.1
Maximum \| Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	67.6	72.5
Weighted average \| Fair value per share of common stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input \| $ / shares	4.70	4.56
Weighted average \| Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input \| $	4.8	5.3
Weighted average \| Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	63.6	63.6

Fair Value Measurements - Finan

Fair Value Measurements - Financial assets that are measured at fair value on a recurring basis (Details) - Recurring - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Level 1
Assets:
Cash equivalents	$ 90,851	$ 13,533
Liabilities:
Total	90,851	13,533
Level 3
Liabilities:
Warrant liability	485	474
Total	$ 485	$ 474

Related Party Transactions (Det

Related Party Transactions (Details)	3 Months Ended		6 Months Ended
Related Party Transactions (Details)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)Vote	Jun. 30, 2020USD ($)	Jan. 31, 2017$ / shares
Commercial Collaboration Agreement
Related Party Transaction [Line Items]
Recognized revenue	$ 0		$ 0
Number of voting members from each party \| Vote			2
LabCorp \| Strategic commercialization agreement \| Maximum
Related Party Transaction [Line Items]
Fees paid	100,000	$ 100,000	$ 100,000	$ 100,000
LabCorp \| Strategic commercialization agreement \| Series C Convertible Preferred Stock
Related Party Transaction [Line Items]
Preferred Stock, par value \| $ / shares					$ 0.0001
Blue Ox \| Consulting agreement
Related Party Transaction [Line Items]
Fees paid	200,000	100,000	300,000	200,000
Healthcore Inc \| Master services agreement
Related Party Transaction [Line Items]
Fees paid	600,000	$ 400,000	800,000	$ 500,000
Anthem \| Laboratory Services Agreement
Related Party Transaction [Line Items]
Recognized revenue	$ 16,000		$ 25,000
Anthem \| Commercial Collaboration Agreement
Related Party Transaction [Line Items]
Term of agreement			3 years

Capital Structure - Common Stoc

Capital Structure - Common Stock (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Deferred offering costs related to an equity offering	$ 2,800	$ 26
Class A common stock
Class of Stock [Line Items]
Shares reserved for future issuance	32,780,798	22,808,979
Class A common stock \| Senior convertible preferred stock
Class of Stock [Line Items]
Shares reserved for future issuance	13,791,579	5,737,440
Class A common stock \| Junior convertible preferred stock
Class of Stock [Line Items]
Shares reserved for future issuance	9,819,480	9,819,480
Class A common stock \| Shares issuable under convertible note
Class of Stock [Line Items]
Shares reserved for future issuance		665,699
Class A common stock \| Warrants to purchase convertible preferred stock
Class of Stock [Line Items]
Shares reserved for future issuance	81,543	81,543
Class A common stock \| Warrants to purchase Class A common stock
Class of Stock [Line Items]
Shares reserved for future issuance	2,741,813	2,019,590
Class A common stock \| Options to purchase Class A common stock
Class of Stock [Line Items]
Shares reserved for future issuance	5,677,611	4,096,722
Class A common stock \| Class A common stock available for future issuance under the 2011 Equity Incentive Plan
Class of Stock [Line Items]
Shares reserved for future issuance	668,772	388,505

Capital Structure - Convertible

Capital Structure - Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Convertible Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	51,551,681	34,368,138
Shares Issued and Outstanding	23,611,059	15,556,920
Aggregate Liquidation Preference	$ 281,751	$ 181,451
Proceeds, net of issuance costs	$ 227,903	$ 128,951
Series A-1 Junior Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	1,390	1,390
Shares Issued and Outstanding	667	667
Original Issue Price Per Share	$ 2,079	$ 2,079
Aggregate Liquidation Preference	$ 1,390	$ 1,390
Proceeds, net of issuance costs	$ 1,390	$ 1,390
Series A-2 Junior Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	7,941,499	7,941,499
Shares Issued and Outstanding	3,803,878	3,803,878
Original Issue Price Per Share	$ 5.20	$ 5.20
Aggregate Liquidation Preference	$ 19,771	$ 19,771
Proceeds, net of issuance costs	$ 19,595	$ 19,595
Series B-1 Junior Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	2,060,000	2,060,000
Shares Issued and Outstanding	961,994	961,994
Original Issue Price Per Share	$ 5.20	$ 5.20
Aggregate Liquidation Preference	$ 5,000	$ 5,000
Proceeds, net of issuance costs	$ 4,914	$ 4,914
Series B-2 Junior Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	5,012,500	5,012,500
Shares Issued and Outstanding	2,404,995	2,404,995
Original Issue Price Per Share	$ 8.32	$ 8.32
Aggregate Liquidation Preference	$ 20,000	$ 20,000
Proceeds, net of issuance costs	$ 19,984	$ 19,984
Series C-1 Junior Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	5,521,905	5,521,905
Shares Issued and Outstanding	2,647,946	2,647,946
Original Issue Price Per Share	$ 12.38	$ 12.38
Aggregate Liquidation Preference	$ 32,755	$ 32,755
Proceeds, net of issuance costs	$ 32,653	$ 32,653
Series C-2 Junior Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	1,510,000	1,510,000
Original Issue Price Per Share	$ 17.22	$ 17.22
Series D Senior Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	11,975,172	12,320,844
Shares Issued and Outstanding	5,737,440	5,737,440
Original Issue Price Per Share	$ 9.03	$ 9.03
Aggregate Liquidation Preference	$ 102,535	$ 102,535
Proceeds, net of issuance costs	$ 50,415	$ 50,415
Series E Senior Preferred Stock
Temporary Equity [Line Items]
Shares Authorized	17,529,215
Shares Issued and Outstanding	8,054,139
Original Issue Price Per Share	$ 12.46
Aggregate Liquidation Preference	$ 100,300
Proceeds, net of issuance costs	$ 98,952

Capital Structure - Conversion

Capital Structure - Conversion Rights (Details) - Series E Senior Convertible Preferred Stock $ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)multiple
Temporary Equity [Line Items]
Increment applied to the original issue price \| multiple	1.2
Minimum gross proceeds required for automatic conversion \| $	$ 40

Capital Structure - Conversio_2

Capital Structure - Conversion price of Convertible Preferred Stock (Details) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Series A-1 Junior Preferred Stock
Temporary Equity [Line Items]
Conversion price	$ 6.08	$ 6.08
Series A-2 Junior Preferred Stock
Temporary Equity [Line Items]
Conversion price	5.20	5.20
Series B-1 Junior Preferred Stock
Temporary Equity [Line Items]
Conversion price	5.20	5.20
Series B-2 Junior Preferred Stock
Temporary Equity [Line Items]
Conversion price	8.32	8.32
Series C-1 Junior Preferred Stock
Temporary Equity [Line Items]
Conversion price	12.38	12.38
Series C-2 Junior Preferred Stock
Temporary Equity [Line Items]
Conversion price	17.22	17.22
Series D Senior Convertible Preferred Stock
Temporary Equity [Line Items]
Conversion price	9.03	$ 9.03
Series E Senior Convertible Preferred Stock
Temporary Equity [Line Items]
Conversion price	$ 12.46

Capital Structure - Additional

Capital Structure - Additional information (Details) - Subsequent event	Jul. 31, 2021shares
Class A common stock
Class of Stock [Line Items]
Shares issued upon conversion of preferred stock	22,434,130
Class B common stock
Class of Stock [Line Items]
Shares issued upon conversion of preferred stock	1,405,259

Stock-based Compensation (Detai

Stock-based Compensation (Details) - shares	1 Months Ended
Stock-based Compensation (Details) - shares	Nov. 30, 2011	Jun. 30, 2021	Dec. 31, 2020
Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future issuance		32,780,798	22,808,979
2011 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant price as a percentage of fair value of the stock	100.00%
Vesting period	4 years
Expiration term	10 years
2011 Plan \| Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future issuance		668,772

Stock-based Compensation - Awar

Stock-based Compensation - Awards 2021 Plan (Details) - Class A common stock - shares	Jun. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance	32,780,798	22,808,979
Plan 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance	3,966,162

Stock-based Compensation - Aw_2

Stock-based Compensation - Awards 2021 ESPP (Details) - Class A common stock - shares	Jun. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance	32,780,798	22,808,979
2021 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance	305,089

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Options (Details)	6 Months Ended	12 Months Ended
Stock-based Compensation - Stock Options (Details)	Jun. 30, 2021$ / sharesshares	Dec. 31, 2020$ / sharesshares
Number of Shares Subject to Options Outstanding
Outstanding at the beginning \| shares	4,096,722
Granted \| shares	1,885,456
Expired \| shares	(63)
Cancelled \| shares	(174)
Exercised \| shares	(304,330)
Outstanding at the end \| shares	5,677,611	4,096,722
Vested and expected to vest at the end \| shares	5,351,674
Vested and exercisable at the end \| shares	2,564,974
Non-vested options at the end \| shares	3,112,538
Weighted-Average Grant Date Fair Value
Outstanding at the beginning (in dollars per share)	$ 0.92
Granted (in dollars per share)	5.54
Expired (in dollars per share)	131.73
Cancelled (in dollars per share)	1.04
Exercised (in dollars per share)	0.55
Outstanding at the end (in dollars per share)	2.47	$ 0.92
Vested and expected to vest at the end (in dollars per share)	2.37
Vested and exercisable at the end (in dollars per share)	1.11
Non-vested options at the end (in dollars per share)	3.59
Weighted-Average Exercise Price Per Share
Outstanding at the beginning (in dollars per share)	1.64
Granted (in dollars per share)	6.72
Expired (in dollars per share)	207.90
Cancelled (in dollars per share)	1.98
Exercised (in dollars per share)	0.87
Outstanding at the end (in dollars per share)	3.37	$ 1.64
Vested and expected to vest at the end (in dollars per share)	3.26
Vested and exercisable at the end (in dollars per share)	1.83
Non-vested options at the end (in dollars per share)	$ 4.63
Weighted-Average Remaining Contractual Life (In Years)
Outstanding (In Years)	7 years 9 months 21 days	6 years 11 months 26 days
Vested and expected to vest at the end	7 years 8 months 15 days
Vested and exercisable at the end	6 years

Stock-based Compensation - Expe

Stock-based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total employee stock-based compensation	$ 864	$ 201	$ 1,103	$ 336
Unamortized stock-based compensation cost	9,500		$ 9,500
Unamortized stock-based compensation cost expected to be recognized over a weighted average period			3 years 4 months 24 days
Research and development expense
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total employee stock-based compensation	370	69	$ 434	123
Sales and marketing expense
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total employee stock-based compensation	117	35	179	64
General and administrative expense
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total employee stock-based compensation	$ 377	$ 97	$ 490	$ 149

Warrants (Details)

Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended		30 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	81,543				81,543		81,543
Additional paid-in capital	$ 864	$ 239	$ 201	$ 135
Fair Value	485				$ 485		$ 485	$ 474
Other income (expense), net	$ 1,072		(4)		$ 1,046	$ 29
Series D Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	22,609				22,609		22,609
Warrant, exercise price	$ 9.03				$ 9.03		$ 9.03
Fair Value	$ 260				$ 260		$ 260	$ 254
Series D Convertible Preferred Stock \| 2019 Warrant
Class of Warrant or Right [Line Items]
Payment of consultant fees							400
Fair Value	200				200		$ 200
Other income (expense), net	$ 4		(10)		(6)	(5)
Warrants \| Series D Convertible Preferred Stock \| Black-Scholes option pricing model
Class of Warrant or Right [Line Items]
Additional paid-in capital					$ 900
Warrant to purchase common stock at $9.03 per share \| Series D Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	1,009,795				1,009,795		1,009,795
Warrant, exercise price	$ 9.03				$ 9.03		$ 9.03
Warrant to purchase common stock at $9.03 per share \| Series D Convertible Preferred Stock \| 2019 Warrant
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	22,609				22,609		22,609	22,609	21,611
Warrant, exercise price									$ 9.03
Warrant to purchase common stock at $10.84 per share \| Series D Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	1,009,795				1,009,795		1,009,795
Warrant, exercise price	$ 10.84				$ 10.84		$ 10.84
Warrant to purchase common stock at $20.77 per share \| Series E Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	722,223				722,223		722,223
Warrant, exercise price	$ 20.77				$ 20.77		$ 20.77
Warrant to purchase common stock at $20.77 per share \| Series E Convertible Preferred Stock \| Black-Scholes option pricing model
Class of Warrant or Right [Line Items]
Additional paid-in capital					$ 1,100
Warrant to purchase convertible preferred stock \| Loan Agreement
Class of Warrant or Right [Line Items]
Vesting period					10 years
Interest expense	$ (5)		$ (4)		$ 5	$ (4)

Warrants - Warrants to purchase

Warrants - Warrants to purchase convertible preferred stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	81,543
Fair Value	$ 485	$ 474
Series A-2 Convertible Preferred Stock Grant Date Sep 2012
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	12,506
Exercise Price	$ 5.20
Fair Value	$ 37	41
Series A-2 Convertible Preferred Stock Grant Date Sep 2014
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	3,473
Exercise Price	$ 5.20
Fair Value	$ 14	13
Series B-1 Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	28,860
Exercise Price	$ 5.20
Fair Value	$ 120	113
Series B-2 Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	6,012
Exercise Price	$ 8.32
Fair Value	$ 23	22
Series C-1 Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	8,083
Exercise Price	$ 12.38
Fair Value	$ 31	31
Series D Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares of common stock	22,609
Exercise Price	$ 9.03
Fair Value	$ 260	254
Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Fair Value	$ 500	$ 500

Warrants - Preferred stock warr

Warrants - Preferred stock warrant liability activity (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Class of Warrant or Right [Line Items]
Outstanding, beginning of period	$ 474
Outstanding, end of period	485
Preferred stock warrant liability
Class of Warrant or Right [Line Items]
Outstanding, beginning of period	474
Outstanding, end of period	485
Preferred stock warrant liability \| Other income (expense), net
Class of Warrant or Right [Line Items]
Net increase in fair value	6
Preferred stock warrant liability \| Interest expense
Class of Warrant or Right [Line Items]
Net increase in fair value	$ 5

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Thousands	6 Months Ended	15 Months Ended	18 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Jun. 30, 2021USD ($)ft²	Jun. 30, 2021USD ($)ft²	Jun. 30, 2021USD ($)ft²	Dec. 31, 2020USD ($)
Loss Contingencies [Line Items]
Renewal period of lease	5 years	5 years	5 years
Percentage of increase in base rent annually	3.00%
Lease rent expense		$ 100	$ 300
Deferred rent	$ 200	200	200	$ 300
Indemnification liability	0	0	0
Current Liabilities
Loss Contingencies [Line Items]
Capital lease obligation payments due	100	100	100
Other Liabilities
Loss Contingencies [Line Items]
Capital lease obligation payments due	$ 100	$ 100	$ 100
Office and laboratory space
Loss Contingencies [Line Items]
Number of square feet under lease \| ft²	24,100	24,100	24,100

Net loss per share - Computatio

Net loss per share - Computation of the basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Net loss per share
Net loss	$ (6,307)	$ (6,359)	$ (4,705)	$ (4,696)	$ (12,666)	$ (9,401)
Weighted-average shares of common stock outstanding, basic and diluted	1,988,886		1,525,648		1,890,908	1,525,491
Earnings Per Share, Basic and Diluted	$ (3.17)		$ (3.08)		$ (6.70)	$ (6.16)

Net loss per share - Anti-dilut

Net loss per share - Anti-dilutive securities excluded from the computation of diluted net loss per share (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of Earnings per share	32,112,026	22,620,508
Junior convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of Earnings per share	9,819,480	9,819,480
Senior convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of Earnings per share	13,791,579	5,737,440
Shares issuable under convertible note
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of Earnings per share		632,733
Warrants to purchase convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of Earnings per share	81,543	81,543
Warrants to purchase Class A common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of Earnings per share	2,741,813	2,019,590
Options to purchase Class A common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of Earnings per share	5,677,611	4,329,722

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent event $ / shares in Units, $ in Millions	Jul. 19, 2021USD ($)$ / sharesshares
Class A common stock
Subsequent Event [Line Items]
Common stock issued from conversion of convertible securities	22,434,130
Class B common stock
Subsequent Event [Line Items]
Common stock issued from conversion of convertible securities	1,405,259
Initial Public Offering
Subsequent Event [Line Items]
Number of shares of common stock issued	4,687,500
Issue price per share \| $ / shares	$ 16
Net proceeds from issuance of common stock \| $	$ 66.6